                         SEQUENCE LISTING

<110>  TG THERAPEUTICS INC., 
       RHIZEN PHARMACEUTICALS SA
       LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
 
<120>  TRIPLE COMBINATION TO TREAT B-CELL MALIGNANCIES  

<130>  3261.015PC03

<150>  US 63/243,708
<151>  2021-09-13

<150>  US 63/113,189
<151>  2020-11-12

<160>  10    
<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Variable heavy chain CDR1

<400>  1

Gly Tyr Thr Phe Thr Ser Tyr Asn 
1               5               


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Variable heavy chain CDR2

<400>  2

Ile Tyr Pro Gly Asn Gly Asp Thr 
1               5               


<210>  3
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Variable heavy chain CDR3

<400>  3

Ala Arg Tyr Asp Tyr Asn Tyr Ala Met Asp Tyr 
1               5                   10      


<210>  4
<211>  118
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Variable heavy chain

<400>  4

Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Gly Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Tyr Asp Tyr Asn Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Ser Val Thr Val Ser Ser 
        115             


<210>  5
<211>  330
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Constant heavy chain

<400>  5

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 
225                 230                 235                 240 


Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  6
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Variable light chain CDR1

<400>  6

Ser Ser Val Ser Tyr 
1               5   


<210>  7
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Variable light chain CDR2

<400>  7

Ala Thr Ser 
1           


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Variable light chain CDR3

<400>  8

Gln Gln Trp Thr Phe Asn Pro Pro Thr 
1               5                   


<210>  9
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Variable light chain

<400>  9

Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 
        35                  40                  45              


Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Ser Tyr Ser Phe Thr Ile Ser Arg Val Glu Ala Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Phe Asn Pro Pro Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 
            100                 105     


<210>  10
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ublituximab Constant light chain

<400>  10

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 
1               5                   10                  15      


Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 
            20                  25                  30          


Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 
        35                  40                  45              


Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 
    50                  55                  60                  


Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 
65                  70                  75                  80  


His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 
                85                  90                  95      


Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            100                 105     


